title: Persistence of antibodies in children after intradermal or intramuscular administration of preexposure primary and booster immunizations with purified Vero cell rabies vaccine.
abstract: BACKGROUND
  The use of intradermal (i.d.) injections of purified Vero cell rabies vaccine (PVRV) for preexposure prophylaxis has not been well-established. We studied the safety and immunogenicity of i.d. and intramuscular (i.m.) PVRV injections for primary and booster preexposure immunizations.
  
  
  METHODS
  One of two rabies preexposure PVRV regimens comprising three doses of either 0.1 ml i.d. or 0.5 ml i.m. administered during 28 days was assigned at random to 190 school children. One booster dose was given 1 year later either i.d. or i.m., according to their initial randomization group. Serologic results were available from 155 (82%) children at 1 year after primary immunization and 118 (62%) children at 2 years after booster.
  
  
  RESULTS
  Although children vaccinated i.d. had significantly lower rabies-neutralizing antibody titers after primary immunization as well as after booster than children vaccinated i.m. (P< 0.001 for all time points), there were no significant differences in the percentages of children with adequate titers (> or =0.15 IU/ml) between the i.d. and i.m. groups after both primary and booster immunizations. Mild local reactions were more frequent after i.d. vaccination. Mild or moderate systemic reactions were infrequent and similar after i.d. and i.m. vaccinations. Fever and headache were reported by < or =6%. The reactions after booster were not different from those of post-primary immunization.
  
  
  CONCLUSIONS
  Purified Vero cell rabies vaccine appears to be safe and immunogenic for primary and booster preexposure immunizations. An i.d. PVRV preexposure regimen should be useful especially for rabies-endemic countries with low per capita income.
authors.affiliation: Department of Tropical Pediatrics, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand. tmasc@mahidol.ac.th
authors.forename: A
authors.initials: A
authors.lastname: Sabchareon
authors.forename: P
authors.initials: P
authors.lastname: Chantavanich
authors.forename: S
authors.initials: S
authors.lastname: Pasuralertsakul
authors.forename: C
authors.initials: C
authors.lastname: Pojjaroen-Anant
authors.forename: V
authors.initials: V
authors.lastname: Prarinyanupharb
authors.forename: P
authors.initials: P
authors.lastname: Attanath
authors.forename: V
authors.initials: V
authors.lastname: Singhasivanon
authors.forename: W
authors.initials: W
authors.lastname: Buppodom
authors.forename: J
authors.initials: J
authors.lastname: Lang
mesh_terms: D000914:Antibodies, Viral / Q000097:blood*; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007117:Immunization, Secondary; D007271:Injections, Intradermal; D007273:Injections, Intramuscular; D008297:Male; D011818:Rabies / Q000517:prevention & control*; D011819:Rabies Vaccines / Q000008:administration & dosage / Q000276:immunology*
chemical_list: D000914:Antibodies, Viral; D011819:Rabies Vaccines